title: Analgesic effect of sustained-release flurbiprofen administered at the site of tissue injury in the oral surgery model.
abstract: Nonsteroidal anti-inflammatory drugs produce their analgesic and adverse effects through interaction with cyclooxygenase in a variety of tissues. The authors evaluated the therapeutic potential of administering a sustained-release formulation of flurbiprofen into a surgical wound following oral surgery to produce analgesia at the site of injury while minimizing exposure to potential targets for toxicity. Subjects (N = 98) received 1 of 8 treatments: flurbiprofen in a microparticle formulation in doses of 3.125 mg, 6.25 mg, 12.5 mg, 25 mg, or 50 mg; PO flurbiprofen 25 mg or 50 mg; or placebo. The flurbiprofen microparticle formulation or matching placebo was placed into the extraction sites at the end of surgery (removal of 2 lower impacted third molars). The sum of the pain visual analog scale over the 6-hour observation period demonstrated significantly less pain (P < .05) for flurbiprofen microparticle in comparison with placebo. Fewer subjects remedicated in the flurbiprofen microparticle drug groups, primarily for the 12.5-mg and higher doses. The incidence of adverse effects and local complications did not differ across groups. These data suggest that direct administration of flurbiprofen in a microparticle formulation at a site of tissue injury delays the onset and lowers the intensity of postoperative pain at lower doses than usually administered orally.
authors.affiliation: National Institute of Dental and Craniofacial Research, National Institute of Health, 10 Center Drive, 1N-103, Bethesda, MD 20892-1197, USA.
authors.forename: Raymond A
authors.initials: RA
authors.lastname: Dionne
authors.forename: Duncan
authors.initials: D
authors.lastname: Haynes
authors.forename: Jaime S
authors.initials: JS
authors.lastname: Brahim
authors.forename: Janet S
authors.initials: JS
authors.lastname: Rowan
authors.forename: Pol-Henri
authors.initials: PH
authors.lastname: Guivarc'h
mesh_terms: D000287:Administration, Topical; D000698:Analgesia / Q000379:methods*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical / Q000145:classification / Q000379:methods; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005480:Flurbiprofen / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D003765:Models, Dental; D010147:Pain Measurement / Q000379:methods; D010149:Postoperative Pain / Q000145:classification / Q000188:drug therapy / Q000209:etiology; D010316:Particle Size; D010519:Periodontium / Q000187:drug effects / Q000293:injuries / Q000601:surgery; D010525:Peripheral Nerves / Q000187:drug effects / Q000502:physiology; D013515:Surgery, Oral; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D003692:Delayed-Action Preparations; D005480:Flurbiprofen